Treatment for Clostridium-difficile Infection With IMM529
Treatment for Clostridium-difficile Infection With IMM529
This study will evaluate the safety and tolerability of IMM-529 together with standard of
 care (SOC) in patients with Clostridium-difficile Infection.
Subjects who provide voluntary written informed consent will be screened for eligibility.
 Subjects meeting all of the inclusion and none of the exclusion criteria will be eligible to
 participate.

 Eligible subjects will be randomized up to 3 weeks post diagnosis of Clostridium-difficile
 Infection given SOC initiated already.

 Each subject will return to the study clinic for assessment and required study procedures on
 Day 7, Day 14, Week 4, Week 8 and Week 12 post randomization. Treatment duration will be 28
 days and follow up will last up to 12 weeks post randomization.
Inclusion Criteria:

 1. Age ≥ 18 years

 2. Unformed stools (≥3 loose stools in 24 hours at diagnosis)

 3. Positive stool testing for C. difficile: PCR and Toxin B positive; or PCR and GDH
 positive.

 4. Up to 3 weeks of diagnosis with at least 20 subjects within 72 hours of diagnosis

 5. Patient or legal representative must have read, understood, and provided written
 informed consent after the nature of the study has been fully explained.

 Exclusion Criteria:

 1. History of chronic diarrheal illness such as ulcerative colitis or Crohn's disease

 2. Known concurrent severe organ insufficiency:

 Liver: Decompensated cirrhosis (Any complication of cirrhosis or Child Score ≥7).

 Cardiovascular: New York Heart Association (NYHA) class IV heart failure, or Ejection
 fraction <30%.

 Respiratory: Severe exercise restriction (ie, unable to climb stairs or perform
 household duties); chronic hypoxia, hypercapnia, severe pulmonary hypertension (>40
 mmHg); or respirator dependency Renal: Receiving chronic dialysis or GFR < 15
 mL/min/1.73m2

 3. Other etiology of diarrhea.

 4. Fulminant CDI, as defined by any of the following attributable to CDI:

 1. Hypotension (Mean arterial pressure < 65mmHg)

 2. Ileus or significant abdominal distention

 3. Toxic megacolon

 4. End organ damage/failure:

 Respiratory - Need for mechanical ventilation. Cardiac - Pulmonary edema. Renal -
 Serum creatinine increase >3x Baseline, GFR decrease >50%, urinary output <0.5mL/kg/hr
 > 12hrs. Hepatic - Liver failure (INR>1.5, Hepatic encephalopathy), decompensation of
 cirrhosis, bilirubin > 2.5mg/dL.

 5. Severe Clostridium difficile colitis with imminent surgery planned in less than 24
 hours.

 6. Immunocompromise due to: immunosuppressants, chemotherapy, radiation in the last 3
 months, long-term steroids (>10mg >3 months) or high-dose steroids (>40mg > 3 weeks),
 leukemia or lymphoma in the last 5 years, or HIV.

 7. Any active malignancy within the last 5 years apart from localized skin cancer
 (squamous cell carcinoma or basal cell carcinoma) that was fully excised.

 8. Positive pregnancy test within 24 hours of study infusion or an unwillingness to
 undergo pregnancy testing in females of child-bearing potential. Females capable of
 child-bearing must agree not to become pregnant from the time of study enrollment
 until at least 28 days after completion of study treatment period. If a woman is
 sexually active and has no history of hysterectomy or tubal ligation, she must agree
 to use 2 acceptable contraceptives (see section 7.4.1.) while participating in the
 study and for 28 days following the last dose of study drug.

 9. Breastfeeding

 10. Receipt of other investigational study agent within previous 30 days.

 11. Cow milk allergy, lactose intolerance or any known or suspected hypersensitivity to
 study products

 12. Any other condition that in the opinion of the investigator would jeopardize the
 safety or rights of the patient participating in the study or make it unlikely the
 patient could complete the study.